Milli-Mark® Anti-CD54-FITC Antibody, clone 6.5B5

Description

• General description: The CD54 antigen is a single chain glycoprotein with a molecular mass of 90 kDa (Springer, 1990). It is the human intercellular adhesion molecule-1 (ICAM-1) belonging to the immunoglobulin supergene family. The ligand for ICAM-1 is LFA-1 (leucocyte function associated-1 protein) (Berendt, 1992). ICAM-1 is widely expressed on many cell types, although the degree of expression by unstimulated resting cells varies. As a cellular activation antigen the expression of ICAM-1 is up-regulated upon cell activation, being induced particularly in response to cytokines such as interleukin-1, tumor necrosis factor, and interferon- (Berendt, 1992; Wellicome, 1990; Thornhill, 1990). ICAM-1 might be a receptor for rhinovirus (Staunton, 1989). In rejecting kidneys the antibody stains all infiltrating cells strongly as well as glomerulus epithelium, endothelium on capillaries, large vessels, and mesangium (Waugh, 1989).
• Specificity: Antibody recognizes Human CD54 antigen.
• Immunogen: TNF-activated human umbilical vein endothelial cells
• Application: Milli-Mark Anti-CD54-FITC Antibody, clone 6.5B5 is an antibody against CD54 for use in FC.
• Quality: Evaluated by flow cytometry using human lymphocytes
• Target description: 90 kDa (Springer, 1990)
• Physical form: Protein A purified
• Storage and Stability: Maintain refrigerated at 2-8°C protected from light in undiluted aliquots for up to 6 months from date of receipt.
• Analysis Note: ControlHuman Lymphocytes
• Legal Information: MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.